Jianfeng Group (600668.SH) subsidiary Meiyashatan oral sustained-release formulation plans to win the bid for national centralized drug procurement.

Zhitong Finance APP news, Jianfeng Group (600668.SH) announced that on July 31, 2026, the company's wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") participated in the bidding work for the twelfth batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office. Jianfeng Pharmaceutical's oral sustained-release formulation of Meqasartan is expected to win the bid in this centralized procurement.